Table 5. Comparison of survivors versus non-survivors with secondary outcome measures.
| Non survivor (59) | Survivor (33) | P-value# | |
|---|---|---|---|
| Age (years) | 49.42±11.02 | 50.85±9.98 | 0.54 |
| Sex male | 51 | 24 | 0.104 |
| Abnormal EEG pattern | |||
| Cerebral dysrhythmias | 5 | 14 | 0.17 |
| Bilateral slowing without triphasic pattern | 7 | 21 | 0.20 |
| Bilateral slowing with triphasic pattern | 13 | 18 | 0.38 |
| SOFA at admission# | 15.85±1.71 | 14.88±1.57 | 0.009 |
| SOFA on day of EEG# | 12.95±1.64 | 11.94±1.67 | 0.006 |
| D SOFA | 2.90±1.51 | 2.94±1.87 | 0.91 |
| Time to intubation* | 3.63±6.51 | 2.97±3.81 | 0.7 |
| Length of ICU stay# | 12.24±6.08 | 11.30±4.41 | 0.47 |
| Length of mechanical ventilation* | 10.93±5.43 | 8.33±3.34 | 0.012 |
| CTP# | 12.71±1.39 | 12.21±1.39 | 0.1 |
| MELD# | 29.75±6.48 | 26.64±5.7 | 0.024 |
| S NH3* | 243.66±127.65 | 200.67±101.18 | 0.11 |
#
Pearson chi-squared p-value was utilized.
*
p value was calculated using Mann–Whitney test. Mean ± standard deviation is reported for Chi-square and Mann–Whitney tests. EEG: electroencephalography; HE: hepatic encephalopathy; SOFA: sequential organ failure assessment score; CTP: Child-Turcotte-Pugh score; MELD: model for end-stage liver disease; S NH3: serum ammonia